1. Home
  2. VAL vs ACAD Comparison

VAL vs ACAD Comparison

Compare VAL & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valaris Limited

VAL

Valaris Limited

HOLD

Current Price

$58.69

Market Cap

3.9B

Sector

Energy

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$25.65

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VAL
ACAD
Founded
1975
1993
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
4.4B
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
VAL
ACAD
Price
$58.69
$25.65
Analyst Decision
Hold
Buy
Analyst Count
5
22
Target Price
$54.80
$30.00
AVG Volume (30 Days)
1.0M
1.2M
Earning Date
02-18-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.53
EPS
5.61
1.54
Revenue
$2,416,000,000.00
$1,047,118,000.00
Revenue This Year
N/A
$15.16
Revenue Next Year
N/A
$11.79
P/E Ratio
$10.14
$16.62
Revenue Growth
6.81
12.69
52 Week Low
$27.15
$13.40
52 Week High
$61.70
$28.35

Technical Indicators

Market Signals
Indicator
VAL
ACAD
Relative Strength Index (RSI) 66.24 43.48
Support Level $55.95 $25.25
Resistance Level $59.54 $27.22
Average True Range (ATR) 2.03 0.94
MACD 0.61 -0.16
Stochastic Oscillator 80.00 18.36

Price Performance

Historical Comparison
VAL
ACAD

About VAL Valaris Limited

Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Share on Social Networks: